Abstract 2708
Background
Docetaxel and cabazitaxel prolong survival in mCRPC however less is known about their utilisation patterns and impact in the setting of androgen receptor-targeted agents (ARTAs; abiraterone and enzalutamide). We evaluated whether receipt of chemotherapy is associated with better survival in pts with mCRPC.
Methods
Optum® de-identified Electronic Health Record dataset was used to identify pts with mCRPC who received first-line docetaxel or an ARTA between 01/05/11 and 30/09/17, followed by chemotherapy (docetaxel, cabazitaxel) and/or ARTA. Pts receiving chemotherapy in ≥ 1 line of treatment (any chemotherapy) vs pts not receiving chemotherapy in any treatment line (no chemotherapy) were assessed. Overall survival (OS) was calculated from start of first-line mCRPC treatment until death from any cause.
Results
In total, 1,961 pts were identified (any chemotherapy 823; no chemotherapy 1,138). Some baseline characteristics differed numerically between treatment groups. Chemotherapy-treated pts had a younger median age, greater pain medication utilisation, more metastases (including liver and lung) and a higher comorbidity score, compared with pts not receiving chemotherapy (Table). For any vs no chemotherapy, median OS was 25.4 months (95% CI 22.3–27.4 ) vs 22.4 months (95% CI 20.4–25.0 ) and the respective 12- and 24-month survival rates were 77.2% (95% CI 0.74–0.80) vs 71.3% (95% CI 0.68–0.74) and 52.1% (95% CI 0.48–0.56) vs 47.4% (95% CI 0.44–0.51).Table:
856P
Any chemotherapy N = 823 | No chemotherapy N = 1138 | |
---|---|---|
Median age at prostate cancer diagnosis, years (range) | 63.2 (25–87) | 68.0 (22–89) |
Median age at first-line mCRPC treatment, years (range) | 70.5 (43–88) | 77.5 (48–90) |
Charlson comorbidity index, median (range) | N = 819 9 (2–18) | N = 1122 8 (0–18) |
Opioid analgesic use at first-line mCRPC treatment, n (%) | 532 (64.6) | 619 (54.4) |
Number of metastases at first-line mCRPC treatment, median (range) | N = 762 7 (1–26) | N = 1032 6 (1–36) |
Visceral metastases, n (%) Liver lung lymph missing | N = 762 57 (7.5) 63 (8.3) 115 (15.1) 61 (3.1) | N = 1032 38 (3.7) 51 (4.9) 111 (10.8) 106 (4.4) |
Conclusions
In this real-world data analysis, less than half of pts with mCRPC received chemotherapy. Pts receiving chemotherapy were younger but had more reported metastases and comorbidities, and were more frequently prescribed pain medication. Despite these higher risk disease characteristics, median OS was observed to be higher in pts receiving any vs no chemotherapy.
Clinical trial identification
Editorial acknowledgement
Danielle Lindley and Mark Cockerill, Meditech Media.
Legal entity responsible for the study
The authors.
Funding
Sanofi.
Disclosure
A.K. Morgans: Honoraria (self): Astellas; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (self): Bayer; Honoraria (self): Sanofi; Honoraria (self): Janssen; Honoraria (self): Genentech. H.A. Divan: Full / Part-time employment: Sanofi. A.J. Birtle: Advisory / Consultancy: Janssen; Advisory / Consultancy, Non-remunerated activity/ies: Astellas; Advisory / Consultancy, Non-remunerated activity/ies: Bayer; Advisory / Consultancy: Sanofi Genzyme; Advisory / Consultancy, Non-remunerated activity/ies: Roche; Advisory / Consultancy: MSD; Non-remunerated activity/ies: Novartis; Non-remunerated activity/ies: Ferring; Non-remunerated activity/ies: Sanofi. T. Dorff: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Janssen; Speaker Bureau / Expert testimony: Exelixis; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Eisai; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Prometheus; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche. A. Ozatilgan: Full / Part-time employment: Sanofi. J.N. Graff: Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Sanofi; Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Merck; Advisory / Consultancy, Research grant / Funding (self): Astellas/Pfizer; Research grant / Funding (self), Investigator initiated trial funding: Janssen; Honoraria (self), Expert witness testimony: Bergman Draper Oslund; Honoraria (self), CME activity: i3 Health.
Resources from the same session
3047 - Health-related quality of life in Greek haematogical malignancies patients undergoing chemotherapy
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract